China shows off homegrown Coronavirus vaccines for first time


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ china-shows-off-homegrown-coronavirus-vaccines-for-first-time
High hopes hang on the small vials of liquid on show at a Beijing trade fair this week -- vaccine candidates produced by Chinese companies Sinovac Biotech and Sinopharm.

China has put its homegrown coronavirus vaccines on display for the first time, as the country where the contagion was discovered looks to shape the narrative surrounding the pandemic.

High hopes hang on the small vials of liquid on show at a Beijing trade fair this week -- vaccine candidates produced by Chinese companies Sinovac Biotech and Sinopharm.

Neither has hit the market yet but the makers hope they will be approved after all-important phase 3 trials as early as year-end.

A Sinovac representative told AFP his firm has already "completed the construction of a vaccine factory" able to produce 300 million doses a year.

On Monday, people at the trade fair crowded around booths showing the potential game-changing vaccines.

China, which is facing a storm of foreign criticism over its early handling of the pandemic, has been trying to repurpose the story of Covid-19.

State media and officials are now emphasizing the revival of Wuhan, the central Chinese city where the deadly pathogen surfaced, as a success story in the fight against the virus.

They are also touting progress on domestic vaccines as a sign of Chinese leadership and resilience in the face of an unprecedented health threat that has pummelled the global economy.

In May, President Xi Jinping pledged to make any potential vaccine developed by China a "global public good".

The potential vaccines on display are among nearly 10 worldwide to enter phase 3 trials, typically the last step ahead of regulatory approval, as countries race to stub out the virus and reboot battered economies.

Sinopharm said it anticipates the antibodies from its jab to last between one and three years -- although the final result will only be known after the trials.

China's nationalistic tabloid Global Times reported last month that "the price of the vaccines will not be high".

Every two doses should cost below 1,000 yuan ($146), the report said, citing Sinopharm's chairman, who told media he has already been injected with one of the candidate vaccines.

China's official Xinhua news agency reported Monday that another vaccine candidate, developed by Chinese military scientists, can deal with mutations in the coronavirus.

As of last month, at least 5.7 billion doses of the vaccines under development around the world had been pre-ordered.

But the World Health Organization has warned that widespread immunization against Covid-19 may not be on the cards until the middle of next year.

Tags : #China #Vaccine #WHO #COVID-19 #First #Hope

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026